Search Result

Pathways Recommended:	TGF-beta/Smad

Results for "

PKC-beta

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (5) AMPK (1) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (2) Apoptosis (22) Arrestin (1) Aurora Kinase (2) Autophagy (8) Bacterial (3) Bcl-2 Family (1) Beta-lactamase (1) c-Kit (4) Calcium Channel (1) CaMK (2) Casein Kinase (1) Caspase (2) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) Cytochrome P450 (2) Dopamine Receptor (1) Dopamine β-hydroxylase (2) Drug Metabolite (2) EGFR (1) Endogenous Metabolite (5) ERK (1) Estrogen Receptor/ERR (2) GLUT (1) Glycosidase (1) GlyT (3) GPR55 (1) GSK-3 (7) HDAC (1) HIV (1) IFNAR (1) IKK (3) Influenza Virus (2) Interleukin Related (1) Isotope-Labeled Compounds (7) JAK (2) JNK (4) Keap1-Nrf2 (2) MARCKS (2) MEK (1) mGluR (1) Monoamine Oxidase (3) mRNA (1) mTOR (1) NF-κB (5) NO Synthase (3) NOD-like Receptor (NLR) (1) p38 MAPK (1) Parasite (1) PARP (1) PDK-1 (2) PI3K (2) PKA (5) PKC (67) Proteasome (1) PTHR (1) RABV (1) Reactive Oxygen Species (ROS) (4) Reference Standards (16) Reverse Transcriptase (2) Sirtuin (1) Small Interfering RNA (siRNA) (2) SphK (1) Syk (2) Tau Protein (1) Telomerase (2) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (3) Tyrosinase (4) VEGFR (3)
By Research Areas:	Cancer (47) Cardiovascular Disease (8) Endocrinology (1) Infection (7) Inflammation/Immunology (17) Metabolic Disease (14) Neurological Disease (20)
Oligonucleotides:	mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Go 6983 Maximum Cited Publications 82 Publications Verification Gö 6983; Goe 6983	PKC	Cancer
Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC₅₀ of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

Midostaurin 35+ Cited Publications PKC412; CGP 41251	PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits *PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ* and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Sotrastaurin 20+ Cited Publications AEB071	MARCKS PKC	Inflammation/Immunology Cancer
Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with K_is of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively .

Ingenol Mebutate 5 Publications Verification Ingenol 3-angelate; PEP005	PKC	Inflammation/Immunology Cancer
Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent *PKC* modulator, with K_is of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.

BX795 35+ Cited Publications	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of PDK1, with an IC₅₀ of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

Hypericin 5+ Cited Publications	Apoptosis Influenza Virus Antibiotic Monoamine Oxidase PKC Cytochrome P450 Dopamine β-hydroxylase Reverse Transcriptase Telomerase	Infection Neurological Disease Cancer
Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of *PKC* (protein kinase C), MAO (monoaminoxidase), *dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450*). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis .

Darovasertib 4 Publications Verification LXS196; IDE196	PKC	Cancer
Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC₅₀ values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research .

Rottlerin Maximum Cited Publications 22 Publications Verification Mallotoxin; NSC 56346; NSC 94525	PKC Autophagy Apoptosis HIV RABV	Infection Cancer
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific *PKC* inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .

Enzastaurin 10+ Cited Publications LY317615	PKC Autophagy Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Enzastaurin (LY317615) is a potent, selective, and CNS-penetrant PKCβ inhibitor with an IC₅₀ of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε .

Endoxifen (Z-isomer) 3 Publications Verification	Estrogen Receptor/ERR Drug Metabolite PKC Akt Apoptosis	Neurological Disease Cancer
Endoxifen Z-isomer hydrochloride, an orally active Tamoxifen (HY-13757A) metabolite, is a selective estrogen receptor modulator with 100-fold more potency than its parent agent, Tamoxifen. Endoxifen Z-isomer inhibits PKCβ1 kinase activity. Endoxifen Z-isomer attenuates PKCβ1-activated AKT ^Ser473 phosphorylation, diminishes AKT substrate phosphorylation, and induces Apoptosis. Endoxifen Z-isomer exhibits anticancer activity against hormone-resistant metastatic breast cancer .

β-N-methylamino-L-alanine hydrochloride 2 Publications Verification BMAA hydrochloride	Bacterial mGluR PKC	Infection Neurological Disease Inflammation/Immunology Cancer
β-N-methylamino-L-alanine hydrochloride (BMAA hydrochloride) is a neurotoxin produced by cyanobacteria. β-N-methylamino-L-alanine hydrochloride activates mGluR3 and inhibits *PKC*. β-N-methylamino-L-alanine hydrochloride can be used in the research of neurodegenerative diseases and immune diseases .

Ro 31-8220 mesylate 10+ Cited Publications Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate	PKC JNK	Cardiovascular Disease Neurological Disease Cancer
Ro 31-8220 mesylate is a potent *PKC* inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 mesylate can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .

TDZD-8 10+ Cited Publications GSK-3β Inhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of *GSK-3β, with an IC₅₀* of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

Daphnetin 5+ Cited Publications 7,8-Dihydroxycoumarin	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species (ROS) Caspase Bcl-2 Family PARP Parasite	Cardiovascular Disease Inflammation/Immunology Cancer
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

Ruboxistaurin 10+ Cited Publications LY333531	PKC	Metabolic Disease
Ruboxistaurin (LY333531) is an orally active, selective **PKC beta inhibitor (K_i*=2 nM). Ruboxistaurin exhibits ATP dependent competitive inhibition of PKC* beta I with an IC₅₀ of 4.7 nM. Ruboxistaurin inhibits PKC beta II with an IC₅₀ of 5.9 nM .

Ruboxistaurin hydrochloride 10+ Cited Publications LY333531 hydrochloride	PKC	Metabolic Disease
Ruboxistaurin (LY333531) hydrochloride is an orally active, selective **PKC beta inhibitor (K_i*=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC* beta I with an IC₅₀ of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC₅₀ of 5.9 nM .

CP21R7 5+ Cited Publications CP21	GSK-3	Cancer
CP21R7 is potent *GSK-3β* inhibitor, with an IC₅₀ of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC₅₀ of 1900 nM.

(-)-Indolactam V 2 Publications Verification Indolactam V	PKC	Cancer
(-)-Indolactam V is a *PKC* activator, with K_is of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and K_ds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity.

Stearoylcarnitine 1 Publications Verification	Endogenous Metabolite PKC GlyT	Neurological Disease Metabolic Disease
Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as *PKC* inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .

Flavanomarein	NF-κB TGF-beta/Smad Syk	Cardiovascular Disease Neurological Disease Metabolic Disease
Flavanomarein is a substance with cytoprotective, anti-inflammatory and antioxidant activities, with a K_a of 3.064e-5 M against human Syk. Flavanomarein enhances the phosphorylation level of AKT, regulates the expression of PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2 and ICAD, and inhibits the nuclear translocation of NF-κB p65. Flavanomarein regulates EMT marker proteins, promotes the proliferation of HK-2 cells, and protects neuronal cells from 6-OHDA-induced neurotoxic damage. Flavanomarein can be used in studies related to Parkinson's disease and diabetic nephropathy.

Bakkenolide A	HDAC TNF Receptor Interleukin Related TGF-β Receptor IFNAR PI3K PKC Akt GSK-3 Caspase Apoptosis	Cancer
Bakkenolide A is an anticancer agent. Bakkenolide A reduces the viability of leukemia cells, inhibits cell colony formation and invasion, and downregulates the expression of HDAC3 in cells. Bakkenolide A downregulates the expression of pro-inflammatory cytokines including TNF-α, interleukins such as *IL-1β, TGF-β1* and IFN-γ, as well as the expression of PI3K, PDK and *PKC* in leukemia cells. Bakkenolide A downregulates activated Akt, GSK and Bad, while upregulates Cyto-c, cleaved Caspase3 and cleaved Caspase7, induces apoptosis (apoptosis) in leukemia cells and thereby inhibits inflammatory responses in leukemia cells. Bakkenolide A significantly slows the growth of subcutaneous leukemia tumors in nude mice. Bakkenolide A is applicable to leukemia-related research .

Plantainoside D 2 Publications Verification	Angiotensin-converting Enzyme (ACE) IKK Calcium Channel PKC Reactive Oxygen Species (ROS) NF-κB Apoptosis Sirtuin NOD-like Receptor (NLR)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Plantainoside D, a phenylethanoid glycosides, is a *IKK-β* inhibitor with diverse biological activities. Plantainoside D shows inhibitory activity of angiotensin-converting enzyme (ACE) with an IC₅₀ of 2.17 mM. Plantainoside D significantly reduces the release of glutamate from nerve terminals in the cerebral cortex of rats by inhibiting the voltage-dependent calcium channel (VDCCs) and protein kinase C (PKC) signaling cascade. Plantainoside D significantly alleviates cell apoptosis by inhibiting the generation of ROS and the activation of NF-κB. Plantainoside D significantly improves acute lung injury (ALI) induced by sepsis by regulating the Sirt3/NLRP3 signaling pathway. Plantainoside D can be used for the study of neuroprotection, antioxidant, anti-inflammation, antihypertension .

Epsilon-V1-2 5 Publications Verification ε-V1-2; EAVSLKPT	PKC	Inflammation/Immunology
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective PKCε inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC .

β-Tocopherol	Tyrosinase	Others
β-Tocopherol is an analogue of vitamin E, exhibits antioxidant properties. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol .

ML192	GPR55 PKC ERK Arrestin	Metabolic Disease
ML192 is a selective ligand antagonist of GPR55. ML192 inhibits the *β-arrestin* trafficking, ERK1/2 phosphorylation and PKCβII translocation .

Endoxifen Z-isomer hydrochloride 3 Publications Verification	Estrogen Receptor/ERR Drug Metabolite PKC Akt Apoptosis	Neurological Disease Cancer
Endoxifen Z-isomer hydrochloride, an orally active Tamoxifen (HY-13757A) metabolite, is a selective estrogen receptor modulator with 100-fold more potency than its parent agent, Tamoxifen. Endoxifen Z-isomer hydrochloride inhibits PKCβ1 kinase activity. Endoxifen Z-isomer hydrochloride attenuates PKCβ1-activated AKT ^Ser473 phosphorylation, diminishes AKT substrate phosphorylation, and induces Apoptosis. Endoxifen Z-isomer hydrochloride exhibits anticancer activity against hormone-resistant metastatic breast cancer .

Punicic acid 1 Publications Verification Trichosanic acid	TNF Receptor GLUT Proteasome Tau Protein PKC	Neurological Disease Metabolic Disease Inflammation/Immunology
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .

PKCβ inhibitor 1 1 Publications Verification	PKC Apoptosis	Cancer
PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC₅₀s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) .

MS-553	PKC	Inflammation/Immunology
MS-553 is a potent, ATP-competitive and reversible inhibitor of conventional *PKC* enzymes with K_is of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC₅₀s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.

TCS 21311 NIBR3049	JAK PKC GSK-3	Cancer
TCS 21311 (NIBR3049) is a potent, highly selective JAK3 inhibitor with an IC₅₀ of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits PKCα, PKCθ, and *GSK3β* with IC₅₀s of 13, 68, and 3 nM, respectively .

Coniferaldehyde 1 Publications Verification 4-Hydroxy-3-methoxycinnamaldehyde	Keap1-Nrf2 Apoptosis	Inflammation/Immunology
Coniferaldehyde (4-Hydroxy-3-methoxycinnamaldehyde) is an effective inducer of heme oxygenase-1 (HO-1). Coniferaldehyde inhibits LPS-induced apoptosis through the PKCα/β II/Nrf-2/HO-1 dependent pathway in RAW264.7 macrophage cells. Coniferaldehyde has antioxidant and anti-inflammatory activities .

Ro 31-8220 formic 10+ Cited Publications Bisindolylmaleimide IX formic	PKC JNK	Cancer
Ro 31-8220 formic is a potent *PKC* inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 formic also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively). Ro 31-8220 formic can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .

SK1-I 1 Publications Verification BML-258	SphK CaMK	Cancer
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a K_i value of 10 μM . SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity .

*His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA*	Endogenous Metabolite Cholinesterase (ChE)	Others
His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .

Ro 31-8220 Bisindolylmaleimide IX	PKC JNK	Cardiovascular Disease Neurological Disease
Ro 31-8220 is a potent *PKC* inhibitor, with IC₅₀s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC₅₀s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .

PKC β pseudosubstrate	PKC	Neurological Disease
PKC β pseudosubstrate is a selective cell-permeable inhibitor of *PKC* .

Hypericin (Standard) 5+ Cited Publications	Reference Standards Apoptosis Influenza Virus Antibiotic Monoamine Oxidase PKC Cytochrome P450 Dopamine β-hydroxylase Reverse Transcriptase Telomerase	Infection Neurological Disease Cancer
Hypericin (Standard) is the analytical standard of Hypericin. This product is intended for research and analytical applications. Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of *PKC* (protein kinase C), MAO (monoaminoxidase), *dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450*). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis .

Malantide 1 Publications Verification	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for *PKC* with a K_m of 16 μM .

9-Methyl-β-carboline	Dopamine Receptor PI3K Monoamine Oxidase	Neurological Disease
9-Methyl-β-carboline is a monoamine oxidase inhibitor and dopaminergic modulator, with an IC₅₀ of 1 μM against human MAO-A and an IC₅₀ of 15.5 μM against human MAO-B. 9-Methyl-β-carboline possesses cognitive enhancement potential and can cross the blood-brain barrier. 9-Methyl-β-carboline increases dopamine levels by inhibiting monoamine oxidase activity and microglial proliferation. 9-Methyl-β-carboline activates *PKA/PKC* and mitochondrial respiratory chain complex I, promotes neurotrophic factor expression and reduces α-synuclein (α-synuclein) levels, thereby reversing neurotoxin-induced dopaminergic neuron damage. 9-Methyl-β-carboline also regulates the PI3K pathway and exerts an anti-proliferative effect on astrocytes. 9-Methyl-β-carboline is widely used in Parkinson's disease-related studies .

Ruboxistaurin mesylate 10+ Cited Publications LY333531 mesylate	PKC	Cardiovascular Disease Metabolic Disease
Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC₅₀ values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes .

Balanol Ophiocordin; Azepinostatin	MARCKS PKA PKC	Others
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human *PKC* isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .

K-252c	Beta-lactamase PKC Bacterial Apoptosis	Infection Cancer
K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable *PKC* inhibitor, with an IC₅₀ of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase .

β-Tocopherol (Standard)	Reference Standards Tyrosinase	Others
β-Tocopherol (Standard) is the analytical standard of β-Tocopherol. This product is intended for research and analytical applications. β-Tocopherol is an analogue of vitamin E, exhibits antioxidant properties. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol .

pTH-Related Protein (1-40) (human, mouse, rat)	PTHR PKC	Endocrinology
pTH-Related Protein (1-40) (human, mouse, rat) stimulates calcium uptake in rat intestinal cells through PTHR1 receptor and *PKCα/β* signaling pathways. pTH-Related Protein (1-40) up-regulates parathyroid hormone 1 receptor (PTHR1) protein, four transcellular calcium transporters, potential vanillin member 6 (TRPV6), calcium-binding protein-D9K (CaBP-D9k), sodium-calcium Exchanger 1 (NCX1) and plasma membrane calcium ATPase 1 (PMCA1) .

Go 6983 (Standard) Gö 6983 (Standard); Goe 6983 (Standard)	PKC Reference Standards	Cancer
Go 6983 (Standard) is the analytical standard of Go 6983. This product is intended for research and analytical applications. Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library

428 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 428 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area

HY-P0154

Epsilon-V1-2 5 Publications Verification ε-V1-2; EAVSLKPT	PKC	Inflammation/Immunology
Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective PKCε inhibitor. Epsilon-V1-2 inhibits the translocationof PKCε, but not α-, β-, and δPKC .

HY-P5189A

*His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA*	Endogenous Metabolite Cholinesterase (ChE)	Others
His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .

HY-P1286

PKC β pseudosubstrate	PKC	Neurological Disease
PKC β pseudosubstrate is a selective cell-permeable inhibitor of *PKC* .

HY-P1597

Malantide 1 Publications Verification	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for *PKC* with a K_m of 16 μM .

HY-P4856

pTH-Related Protein (1-40) (human, mouse, rat)	PTHR PKC	Endocrinology
pTH-Related Protein (1-40) (human, mouse, rat) stimulates calcium uptake in rat intestinal cells through PTHR1 receptor and *PKCα/β* signaling pathways. pTH-Related Protein (1-40) up-regulates parathyroid hormone 1 receptor (PTHR1) protein, four transcellular calcium transporters, potential vanillin member 6 (TRPV6), calcium-binding protein-D9K (CaBP-D9k), sodium-calcium Exchanger 1 (NCX1) and plasma membrane calcium ATPase 1 (PMCA1) .

HY-P1286A

PKC β pseudosubstrate TFA	PKC	Neurological Disease
PKC β pseudosubstrate TFA is a selective cell-permeable inhibitor of *PKC* .

HY-P1371

Pseudo RACK1 KKWKMRRNQFWIKIQRC CSVEIWD*	PKC	Others
Pseudo RACK1, a peptide, is a *PKC* agonist with homologous sequences of PKC. Pseudo RACK1 interacts selectively with β-PKC at an autoregulatory site (RACK-binding site) and activates it in the absence of PKC activators, following inducing PKC-mediated histone phosphorylation .

HY-P3842

Protein Kinase C (661-671)	PKC	Cancer
Protein Kinase C (661-671) is a fragment peptide of β1 subspecies of protein kinase C (PKC). PKC plays a role in cellular growth control and tumor promotion .

HY-P10821

Myr-Tat-PKCβII	PKC Reactive Oxygen Species (ROS)	Cardiovascular Disease
Myr-Tat-PKCβII is a cell permeable protein kinase C β II peptide inhibitor. Myr-Tat-PKCβII mitigates the generation of reactive oxygen species in rat ex-vivo and porcine in-vivo ischemia-reperfusion injury .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for *PKC* with a K_m of 16 μM .

Species:	Human (2)
Tag:	His (1) GST (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705566

	PRKCB2 Protein, Human (Active, sf9, His-GST) Protein kinase C beta type; PKC-B; PKC-beta; PRKCB; PKCB; EC:2.7.11.13	Human	Sf9 insect cells

HY-P702639

	PRKCB1 Protein, Human (Active, sf9, GST) PRKCB1; protein kinase C, beta; PKCB, PRKCB1, PRKCB2, protein kinase C, beta 1; protein kinase C beta type; PKC-B; protein kinase C, beta 1 polypeptide; PKCB; PRKCB1; PRKCB2; PKC-beta; MGC41878	Human	Sf9 insect cells
	PRKCB1 Protein, Human (sf9, GST) is the recombinant human-derived PRKCB, expressed by Sf9 insect cells , with GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10230S

Midostaurin-d5
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM .

HY-10195BS

Ruboxistaurin-d6 hydrochloride

Ruboxistaurin-d₆ (hydrochloride) is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC₅₀ of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC₅₀ of 5.9 nM .

HY-113202S

Stearoyl-L-carnitine-d3

Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .

HY-W751179

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-113068S

β-Tocopherol-d3
β-Tocopherol-d₃ is the deuterium labeled β-Tocopherol. β-Tocopherol is an analogue of vitamin E, exhibits antioxidant properties. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol can also prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol .

HY-113202S1

Stearoyl-L-carnitine-d9 chloride

Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

HY-133680S

β-Tocopherol-d4
β-Tocopherol-d4 is a deuterium labeled β-Tocopherol (HY-133680). β-Tocopherol is an analogue of vitamin E, exhibits antioxidant properties. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol .

Host:	Rabbit (5)
Reactivity:	Human (5) Rat (3) Mouse (5)
Application:	IHC-P (5) ICC/IF (3) IP (1) WB (5) FC (3) Dot Blot (1)
Isotype:	IgG (5)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Phosphorylated (2) Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80432

	PKC beta 2 Antibody (YA129)	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	PKC beta 2 Antibody (YA129) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKC beta 2.

HY-P810650

	Phospho-PKC (Ser729) Antibody (YA9910) KPCA_HUMAN; PKC alpha; PKC beta; PKC delta; PKC epsilon; PKC gamma; PKC zeta; PKC-A; PKC-alpha; PKC2	WB, IHC-P	Human, Mouse, Rat
	Phospho-PKC (Ser729) Antibody (YA9910) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-PKC (Ser729).

HY-P80431

	PKC beta 1 Antibody (YA130)	WB, IHC-P, FC	Human, Mouse
	PKC beta 1 Antibody (YA130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKC beta 1.

HY-P810727

	PKC beta Antibody (YA9971) PKCA, PRKACA, PRKCA, Protein kinase C alpha type, PKC-A, PKC-alpha	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	PKC beta Antibody (YA9971) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to PKC beta Antibody.

HY-P810622

	*Phospho-PKC* alpha/beta II (Thr638/T641) Antibody (YA9884)** PRKCA; PKCA; PRKACA; Protein kinase C alpha type; PKC-A; PKC-alpha	WB, IHC-P, ICC/IF, FC, Dot Blot	Human, Mouse, Rat
	Phospho-PKC alpha/beta II (Thr638/T641) Antibody (YA9884) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-PKC alpha/beta II (Thr638/T641).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS11119

PRKCB Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
PRKCB Human Pre-designed siRNA Set A contains three designed siRNAs for PRKCB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS11120

Prkcb Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Prkcb Mouse Pre-designed siRNA Set A contains three designed siRNAs for Prkcb gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-174542

Human PRKCB mRNA		mRNA
Human PRKCB mRNA encodes the human protein kinase C beta (PRKCB) protein, a member of Protein kinase C (PKC) family. PRKCB has been reported to be involved in many different cellular functions, such as B cell activation, apoptosis induction, endothelial cell proliferation, and intestinal sugar absorption.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks